About HCell Inc.
Non-Surgical
|
HCell Inc. (“HCell”) is a biotechnology company based in Austin, Texas, focusing on development of medical hair restoration for alopecia areata patients in the pediatric population as well as androgenic alopecia in men and women. HCell has in the pipeline products that are poised to be a major game-changer within the enormous market of potential consumers, more than 80 million men and women in the U.S. alone.
Over 60% of men and women will eventually suffer from hair loss. HCell products uniquely combine the science of medicine and biologics in order to induce regenerative cellular activities, thereby helping to restore normal hair growth cycles. |
Milestone Strategy
|
HCell is working diligently to get ready to conduct the clinical study for this significant, yet unmet, medical need for Alopecia Areata in pediatric patients with HC017AA and Androgenic Alopecia with HC0100.
HCell’s business will be marketed to consumers via a network of professional medical providers including highly reputable plastic surgeons, dermatologists and medical spas. Our licensee/franchisee business model minimizes corporate overhead and capitalizes on the professional reputations and deep patient pools of our providers. HCell is ramping up continued research, business operations, and sales and marketing. An experienced management team will swiftly navigate the company through any obstacles and challenges standing in the way of reaching our $1.13 billion revenue estimates by the end of year five in full-scale operation. We are seeking prospective investors to help raise equity capital to start the FDA process and initial business operations in the U.S. Given the size of the global hair restoration market ($80 billion and growing) and our realistic, if not conservative, financial projections, investing in HCell is a low-risk and high-reward opportunity for the savvy, business-minded backer.
|